title: Reply to Eschenauer et al.
authors.affiliation: Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts.
authors.forename: Ravina
authors.initials: R
authors.lastname: Kullar
authors.affiliation: Infectious Disease Clinical Outcomes Unit, Los Angeles Biomedical Research Institute, David Geffen School of Medicine, University of California Torrance Memorial Medical Center, California.
authors.forename: James A
authors.initials: JA
authors.lastname: McKinnell
authors.affiliation: Division of Pediatric Pharmacology and Drug Discovery, University of California, San Diego School of Medicine, La Jolla.
authors.forename: George
authors.initials: G
authors.lastname: Sakoulas
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents